The present disclosure relates to boron-based 4-hydroxytamoxifen and endoxifen prodrugs and the synthesis of the same. Further, the present disclosure teaches the utilization of the boron-based 4-hydroxytamoxifen and endoxifen prodrugs in a treatment for breast cancer. wherein R 1 is KF 3 B, (HO) 2 B, NaF 3 B, wherein the R 1 substituent point of attachment is on the Boron atom; and R 2 is methyl or hydrogen.